

## Accepted Manuscript

Title: Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers

Author: <ce:author id="aut0005" author-id="S1043661817300166-f9866cf30d73cde1771a72979b3be151"> Robert Roskoski Jr.



PII: S1043-6618(17)30016-6  
DOI: <http://dx.doi.org/doi:10.1016/j.phrs.2017.01.007>  
Reference: YPHRS 3468

To appear in: *Pharmacological Research*

Received date: 5-1-2017  
Accepted date: 6-1-2017

Please cite this article as: Roskoski Robert. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. *Pharmacological Research* <http://dx.doi.org/10.1016/j.phrs.2017.01.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers

Robert Roskoski Jr.

Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, North Carolina 28742-8814, United States

Phone: 1-828-891-5637

Fax: 1-828-890-8130

E-mail address: [rrj@brimr.org](mailto:rrj@brimr.org)

Download English Version:

<https://daneshyari.com/en/article/5557395>

Download Persian Version:

<https://daneshyari.com/article/5557395>

[Daneshyari.com](https://daneshyari.com)